-+ 0.00%
-+ 0.00%
-+ 0.00%

VERASTEM ONCOLOGY ANNOUNCES TWO-YEAR MEDIAN FOLLOW-UP DATA ON AVMAPKI® FAKZYNJA® COMBINATION THERAPY (AVUTOMETINIB CAPSULES; DEFACTINIB TABLETS) IN RECURRENT LOW-GRADE SEROUS OVARIAN CANCER AT THE SGO 2026 ANNUAL MEETING ON WOMEN’S CANCERS

Reuters·04/10/2026 11:00:01

Please log in to view news